echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Nat Commun: Clinical trials have confirmed that tocilizumab can be used to relieve pre-transplant syndrome

    Nat Commun: Clinical trials have confirmed that tocilizumab can be used to relieve pre-transplant syndrome

    • Last Update: 2021-08-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Hematopoietic stem cell transplantation (HSCT) is currently an effective treatment for hematological malignancies (leukemia, myeloma, and lymphoma ) and other hematological diseases (myelodysplasia and aplastic anemia)
    .


    However, in view of the widespread nature of human leukocyte antigen (HLA) polymorphisms and the small-scale nature of modern families, most patients requiring hematopoietic stem cell transplantation do not have an HLA-matched donor


    Stem cell lymphoma

    HLA-haploid transplantation has rapidly spread worldwide, and cord blood (CB) is also a good alternative source of hematopoietic stem cells
    .


    Umbilical cord blood has many advantages as a source of stem cells


    immunity

    More and more evidence shows that for patients who lack relatives and HLA-matched non-relative donors, haploid donors and CB are promising options
    .


    Although the recovery of hematopoietic function is delayed, the incidence of acute graft-versus-host disease (aGVHD) and chronic GVHD (cGVHD) is lower in UCBT recipients


    Unfortunately, UCBT is usually accompanied by the emergence of unique early immune responses that have appeared before neutrophil transplantation
    .


    Lee et al.


    Severe PES cases are associated with increased mortality and morbidity.


    GM-CSF produced by inflammatory monocytes in cord blood drives the pathological changes of PES.


    Clinical symptoms and manifestations before and after treatment with tocilizumab

    Clinical symptoms and manifestations before and after treatment with tocilizumab Clinical symptoms and manifestations before and after treatment with tocilizumab

    In addition, the researchers also reported the results of a single-arm, single-center clinical study of tocilizumab in the treatment of steroid-refractory severe PES patients ( ChiCTR1800015472)
    .


    The study reached the main outcome indicator because none of the patients had a non-recurring death during the 100-day follow-up


    Single-arm, single-center clinical research results Single-arm, single-center clinical research results reached the main outcome indicators reached the main outcome indicators reached the key secondary outcome indicators for neutrophil transplantation and hematopoiesis reached the neutrophil transplantation and hematopoiesis Key secondary outcome indicators

    These findings provide a treatment strategy for solving PES and improving non-relapse mortality


     

    Original source:

    Original source:

    Linlin Jin et al.


    Linlin Jin et al.


     

    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.